Influence of depressive sy mptoms on dopaminergic treatment of Parkinson's disease

Frontiers in Neurology

Volumn 5, Issue SEP, 2014, Pages

  Hanganu, Alexandru ^a   Degroot, Clotilde ^a   Monchi, Oury ^a,f   Bedetti, Christophe ^b   Mejia Constain, Béatriz ^a   Lafontaine, Anne Louise ^c,d   Chouinard, Sylvain ^e   Bruneau, Marie Andrée ^a  

^a CENTRE DE RECHERCHE   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Depressive symptoms; Dopamine agonists; L DOPA; Parkinson's disease

Indexed keywords

BENSERAZIDE; CARBIDOPA; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; ANALYSIS OF VARIANCE; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG OVERDOSE; FEMALE; HUMAN; MALE; MONTREAL COGNITIVE ASSESSMENT; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84907946058     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00188     Document Type: Article

References (94)

1. Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 62(1):10-5. doi: 10.1136/jnnp.62.1.10.
2. von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 15(4):473-90. doi: 10.1016/j.euroneuro.2005.04.007.
3. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord (2007) 22(13):1901-11. doi: 10.1002/mds.21596.
4. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci (2006) 248(1-2):151-7. doi: 10.1016/j.jns.2006.05.030.
5. Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson's disease: A systematic review. Parkinsonism Relat Disord (2011) 17(1):1-9. doi: 10.1016/j.parkreldis.2010.08.012.
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology (1967) 17(5):427.
7. Mallet L, Allart E. Le traitement de la dépression dans la maladie de Parkinson. Pharmactuel (2004) 37(2):83-9.
8. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 23(2):183-9. doi: 10.1002/mds.21803.
9. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Mov Disord (2006) 21(2):148-58. doi: 10.1002/mds.20723.
10. Poewe W, Luginger E. Depression in Parkinson's disease: Impediments to recognition and treatment options. Neurology (1999).
11. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord (2010) 25(15):2493-500. doi: 10.1002/mds.23394.
12. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry (2000) 69(3):308-12. doi: 10.1136/jnnp.69.3.308.
13. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 67(4):492-6. doi: 10.1136/jnnp.67.4.492.
14. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci (2001) 13(2):187-96. doi: 10.1176/appi.neuropsych.13.2.187.
15. Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M, on behalf of the P-PDSG. Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease? Mov Disord (2012) 27(2):236-41. doi: 10.1002/mds.23961.
16. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology (1997) 49(4):1168-70.
17. Ehrt U, Brønnick K, Leentjens AFG, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry (2006) 21(3):252-8. doi: 10.1002/gps.1456.
18. Erdal KJ. Depressive symptom patterns in patients with Parkinson's disease and other older adults. J Clin Psychol (2001) 57(12):1559-69. doi: 10.1002/jclp.1118.
19. Merschdorf U, Berg D, Csoti I, Fornadi F, Merz B, Naumann M, et al. Psychopathological Symptoms of Depression in Parkinson's Disease Compared to Major Depression. Psychopathology (2003) 36(5):221-5. doi: 10.1159/000073446.
20. Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord (2007) 22(8):1077-92. doi: 10.1002/mds.21333.
21. Fung VSC, Herawati L, Wan Y. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord (2009) 24(1):25-31. doi: 10.1002/mds.21878.
22. Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. J Neuropsychiatry Clin Neurosci (2006) 18(3):397-401. doi: 10.1176/appi.neuropsych.18.3.397.
23. Marsh GG, Markham CH. Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry (1973) 36(6):925-35. doi: 10.1136/jnnp.36.6.925.
24. Kim H-J, Park S-Y, Cho Y-J, Hong K-S, Cho J-Y, Seo S-Y, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci (2009) 287(1-2):200-4. doi: 10.1016/j.jns.2009.07.026.
25. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment. Neurosci Biobehav Rev (2011) 35(3):556-64. doi: 10.1016/j.neubiorev.2010.06.007.
26. Choi C, Sohn YH, Lee JH, Kim J-S. The effect of long- term levodopa therapy on depression level in de novo patients with Parkinson's disease. J Neurol Sci (2000) 172(1):12-6. doi: 10.1016/S0022-510X(99)00198-7.
27. Navailles S, Bioulac B, Gross C, De Deurwaerdère P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis (2011) 41(2):585-90. doi: 10.1016/j.nbd.2010.11.007.
28. Hinz M, Stein A, Uncini T. Amino acid management of Parkinson's disease: a case study. Int J Gen Med (2011) 4:165. doi: 10.2147/IJGM.S16621.
29. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology (2010) 75(12):1062-9. doi: 10.1212/WNL.0b013e3181f39d0e.
30. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the cardiovascular health study. Arch Gen Psychiatry (2006) 63(3):273-9. doi: 10.1001/archpsyc.63.3.273.
31. Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lépine JP, et al. Anxious and depressive symptoms in Parkinson's disease: The French cross-sectionnal DoPaMiP study. Mov Disord (2010) 25(2):157-66. doi: 10.1002/mds.22760.
32. Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry (2012) 25(6):468-72. doi: 10.1097/YCO.0b013e3283577ed1.
33. Thomas AJ, O'Brien JT. Depression and cognition in older adults. Curr Opin Psychiatry (2008) 21(1):8-13. doi: 10.1097/YCO.0b013e3282f2139b.
34. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology (2010) 75(1):27-34. doi: 10.1212/WNL.0b013e3181e62124.
35. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol (2010) 626(1):64-71. doi: 10.1016/j.ejphar.2009.10.022.
36. Anguenot A, Loll PY, Neau JP, Ingrand P, Gil R. Depression and Parkinson's Disease: study of a series of 135 Parkinson's patients. Can J Neurol Sci (2002) 29(2):139-46.
37. Huber SJ, Paulson GW, Shuttleworth EC. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 51(6):855-8. doi: 10.1136/jnnp.51.6.855.
38. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology (1986) 36(8):1130-. doi: 10.1212/WNL.36.8.1130.
39. Evans A, Lawrence AD, Potts J, Appel S, Lees A. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology (2005) 65(10):1570-4.
40. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol (2008) 64(S2):S93-S100. doi: 10.1002/ana.21454.
41. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 59(5):852-8.
42. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev (2006) 30(1):1-23. doi: 10.1016/j.neubiorev.2005.03.024.
43. MacDonald PA, MacDonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost J-S, et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain (2011) 134(5):1447-63. doi: 10.1093/brain/awr075.
44. Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord (2006) 21(12):2206-8. doi: 10.1002/mds.21110.
45. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 55(3):181-4. doi: 10.1136/jnnp.55.3.181.
46. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.
47. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 27(3):349-56. doi: 10.1002/mds.24893.
48. Kish SJ, Shannak K, Hornykiewicz O. Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease. N Engl J Med (1988) 318(14):876-80. doi: 10.1056/NEJM198804073181402. PubMed PMID: 3352672.
49. Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry (2005) 62(11):1228. doi: 10.1001/archpsyc.62.11.1228.
50. Epstein J, Pan H, Kocsis J, Yang Y, Butler T, Chusid J, et al. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry (2006) 163(10):1784-90.
51. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or Impaired Cognitive Function in Parkinson's Disease as a Function of Dopaminergic Medication and Task Demands. Cereb Cortex (2001) 11(12):1136- doi: 10.1093/cercor/11.12.1136.
52. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck Depression Inventories-IA and-II in Psychiatric Outpatients. J Pers Assess (1996) 67(3):588-97. doi: 10.1207/s15327752jpa6703_13.
53. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation. Tucson, AZ: Neuropsychology Press (1985).
54. Wechsler D. Wechsler adult intelligence scale-III (WAIS-III). New York: Psychological Corporation (1997).
55. Golden CJ, Freshwater SM. Stroop Color and Word Test: A manual for clinical and experimental uses. Wood Dale, IL: Stoelting Co (1998).
56. Culbertson CW, Zillmer EA. Tower of London Drexel University (TOL DX). North Tonawanda, NY: Multi-Health Systems Incorporated (MHS) (2005).
57. Burgess PW, Shallice T. The hayling and brixton tests. Test manual. Bury St Edmunds, UK: Thames Valley Test Company (1997).
58. Joanette Y, Ska B, Côté H. Protocole Montréal d'évaluation de la communication (Protocole MEC). Isbergues, France: Ortho Édition (2004).
59. Wechsler D. Wechsler abbreviated scale of intelligence (WASI). San Antonio, Tex: Psychological Corporation (1999).
60. Kaplan E, Goodglass H, Weintraub S. Boston naming test. Philadelphia: Lea & Febiger (1983).
61. Schmidt M. Rey auditory verbal learning test: A handbook. Los Angeles, CA: Western Psychological Services (1996).
62. Hooper HE. The Hooper Visual Organization Test. Los Angeles, CA: Western Psychological Services (1958).
63. Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry (2000) 15(6):548-61. doi: 10.1002/1099-1166(200006)15:6<548::aid-gps242>3.0.co;2-u.
64. Shulman KI, Pushkar Gold D, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: A longitudinal study. Int J Geriatr Psychiatry (1993) 8(6):487-96. doi: 10.1002/gps.930080606.
65. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the Beck depression inventory-II in clinically depressed outpatients. J Clin Psychol (1999) 55(1):117-28. doi: 10.1002/(sici)1097-4679(199901)55:1<117::aid-jclp12>3.0.co;2-a.
66. Storch EA, Roberti JW, Roth DA. Factor structure, concurrent validity, and internal consistency of the beck depression inventory-second edition in a sample of college students. Depress Anxiety (2004) 19(3):187-9. doi: 10.1002/da.20002.
67. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika (1988) 75(4):800-2. doi: 10.1093/biomet/75.4.800.
68. Zahodne LB, Marsiske M, Okun MS, Bowers D. Components of Depression in Parkinson Disease. J Geriatr Psychiatr Neurol (2012) 25(3):131-7. doi: 10.1177/0891988712455236.
69. Starkstein SE, Preziosi TJ, Forrester AW, Robinson RG. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 53(10):869-73. doi: 10.1136/jnnp.53.10.869.
70. Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry (1988) 145(8):1020-2.
71. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, et al. Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression. Biol Psychiatry (2010) 67(2):110-6. doi: 10.1016/j.biopsych.2009.09.013.
72. Brog JS, Salyapongse A, Deutch AY, Zahm DS. The patterns of afferent innervation of the core and shell in the "Accumbens" part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol (1993) 338(2):255-78. doi: 10.1002/cne.903380209.
73. Zahm DS, Brog JS. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience (1992) 50(4):751-67. doi: 10.1016/0306-4522(92)90202-D.
74. McGeorge AJ, Faull RLM. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience (1989) 29(3):503-37. doi: 10.1016/0306-4522(89)90128-0.
75. Pennartz C, Groenewegen HJ, Lopes da Silva FH. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol (1994) 42(6):719-61.
76. Nicola SM, Deadwyler SA. Firing rate of nucleus accumbens neurons is dopamine-dependent and reflects the timing of cocaine-seeking behavior in rats on a progressive ratio schedule of reinforcement. J Neurosci (2000) 20(14):5526-37.
77. O'Donnell P, Greene J, Pabello N, Lewis BL, Grace AA. Modulation of Cell Firing in the Nucleus Accumbens. Ann N Y Acad Sci (1999) 877(1):157-75. doi: 10.1111/j.1749-6632.1999.tb09267.x.
78. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol (2006) 5(3):235-45. doi: 10.1016/S1474-4422(06)70373-8.
79. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol (2008) 15:14-20. doi: 10.1111/j.1468-1331.2008.02056.x.
80. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol (2008) 64(S2):S65-S80. doi: 10.1002/ana.21472.
81. Le Moal M, Koob GF. Drug addiction: Pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol (2007) 17(6-7):377-93. doi: 10.1016/j.euroneuro.2006.10.006.
82. Popescu AT, Popa D, Pare D. Coherent gamma oscillations couple the amygdala and striatum during learning. Nat Neurosci (2009) 12(6):801-7. doi: 10.1038/nn.2305.
83. Popa D, Duvarci S, Popescu AT, Léna C, Paré D. Coherent amygdalocortical theta promotes fear memory consolidation during paradoxical sleep. Proc Natl Acad Sci (2010) 107(14):6516-9. doi: 10.1073/pnas.0913016107.
84. Berke JD. Fast oscillations in cortical-striatal networks switch frequency following rewarding events and stimulant drugs. Eur J Neurosci (2009) 30(5):848-59. doi: 10.1111/j.1460-9568.2009.06843.x.
85. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci (2009) 10(8):561-72.
86. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. British Journal of Pharmacology (2008) 154(2):384-96. doi: 10.1038/bjp.2008.100.
87. Lüscher C, Malenka Robert C. Drug-Evoked Synaptic Plasticity in Addiction: From Molecular Changes to Circuit Remodeling. Neuron (2011) 69(4):650-63. doi: 10.1016/j.neuron.2011.01.017.
88. Wu K, Politis M, Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J (2009) 85(1009):590-6. doi: 10.1136/pgmj.2008.075820.
89. Ambermoon P, Carter A, Hall WD, Dissanayaka NNW, O'Sullivan JD. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction (2011) 106(2):283-93. doi: 10.1111/j.1360-0443.2010.03218.x.
90. Chen JJ, Marsh L. Depression in Parkinson's Disease: Identification and Management. Pharmacotherapy (2013) 33(9):972-83. doi: 10.1002/phar.1314.
91. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244.
92. Perez-Lloret S, Rascol O. Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol (2012) 8(7):365-6. doi: 10.1038/nrneurol.2012.111.
93. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression i n Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord (2003) 10(1):23-8.
94. Kuhn W, Heye N, Müller T, Kraus P, Klotz P, Friedrich B, et al. The motor performance test series in Parkinson's disease is influenced by depression. J Neural Transm (1996) 103(3):349-54. doi: 10.1007/BF01271246.